179 related articles for article (PubMed ID: 23724064)
1. Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa.
Yelskaya Z; Carrillo V; Dubisz E; Gulzar H; Morgan D; Mahajan SS
PLoS One; 2013; 8(5):e64588. PubMed ID: 23724064
[TBL] [Abstract][Full Text] [Related]
2. The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity.
Fitzjohn SM; Bortolotto ZA; Palmer MJ; Doherty AJ; Ornstein PL; Schoepp DD; Kingston AE; Lodge D; Collingridge GL
Neuropharmacology; 1998 Dec; 37(12):1445-58. PubMed ID: 9886667
[TBL] [Abstract][Full Text] [Related]
3. β-Elemene enhances the efficacy of gefitinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway.
Mu L; Wang T; Chen Y; Tang X; Yuan Y; Zhao Y
Int J Oncol; 2016 Oct; 49(4):1427-36. PubMed ID: 27498706
[TBL] [Abstract][Full Text] [Related]
4. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats.
Feinberg I; Schoepp DD; Hsieh KC; Darchia N; Campbell IG
J Pharmacol Exp Ther; 2005 Feb; 312(2):826-33. PubMed ID: 15383637
[TBL] [Abstract][Full Text] [Related]
5. LY341495, an mGluR2/3 Antagonist, Regulates the Immunosuppressive Function of Myeloid-Derived Suppressor Cells and Inhibits Melanoma Tumor Growth.
Morikawa N; Tachibana M; Ago Y; Goda H; Sakurai F; Mizuguchi H
Biol Pharm Bull; 2018; 41(12):1866-1869. PubMed ID: 30504687
[TBL] [Abstract][Full Text] [Related]
6. Pre- and Postsynaptic Effects of Glutamate in the Frog Labyrinth.
Rossi ML; Rubbini G; Martini M; Canella R; Fesce R
Neuroscience; 2018 Aug; 385():198-214. PubMed ID: 29913242
[TBL] [Abstract][Full Text] [Related]
7. Actions of LY341495 on metabotropic glutamate receptor-mediated responses in the neonatal rat spinal cord.
Howson PA; Jane DE
Br J Pharmacol; 2003 May; 139(1):147-55. PubMed ID: 12746233
[TBL] [Abstract][Full Text] [Related]
8. Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
Watt HL; Rachid Z; Jean-Claude BJ
J Neurooncol; 2010 Dec; 100(3):345-61. PubMed ID: 20467786
[TBL] [Abstract][Full Text] [Related]
9. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
Shien T; Doihara H; Hara H; Takahashi H; Yoshitomi S; Taira N; Ishibe Y; Teramoto J; Aoe M; Shimizu N
Breast Cancer; 2004; 11(4):367-73. PubMed ID: 15604992
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
Ren W; Korchin B; Zhu QS; Wei C; Dicker A; Heymach J; Lazar A; Pollock RE; Lev D
Clin Cancer Res; 2008 May; 14(9):2785-95. PubMed ID: 18451246
[TBL] [Abstract][Full Text] [Related]
11. The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells.
Al-Hazzaa A; Bowen ID; Randerson P; Birchall MA
Cell Prolif; 2005 Apr; 38(2):77-86. PubMed ID: 15842252
[TBL] [Abstract][Full Text] [Related]
12. Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines.
Rosetti M; Tesei A; Ulivi P; Fabbri F; Vannini I; Brigliadori G; Granato AM; Amadori D; Zoli W
Cancer Biol Ther; 2005 Oct; 4(10):1089-95. PubMed ID: 16082196
[TBL] [Abstract][Full Text] [Related]
13. Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.
Rosetti M; Zoli W; Tesei A; Ulivi P; Fabbri F; Vannini I; Brigliadori G; Granato AM; Amadori D; Silvestrini R
J Cell Physiol; 2007 Sep; 212(3):710-6. PubMed ID: 17458894
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
15. Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.
Liao S; Ruiz Y; Gulzar H; Yelskaya Z; Ait Taouit L; Houssou M; Jaikaran T; Schvarts Y; Kozlitina K; Basu-Roy U; Mansukhani A; Mahajan SS
PLoS One; 2017; 12(2):e0171256. PubMed ID: 28231291
[TBL] [Abstract][Full Text] [Related]
16. Activation of Group II Metabotropic Glutamate Receptors Increases Proliferation but does not Influence Neuronal Differentiation of a Human Neural Stem Cell Line.
Dindler A; Blaabjerg M; Kamand M; Bogetofte H; Meyer M
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):367-372. PubMed ID: 29024451
[TBL] [Abstract][Full Text] [Related]
17. Glutamate promotes cell growth by EGFR signaling on U-87MG human glioblastoma cell line.
Schunemann DP; Grivicich I; Regner A; Leal LF; de Araújo DR; Jotz GP; Fedrigo CA; Simon D; da Rocha AB
Pathol Oncol Res; 2010 Jun; 16(2):285-93. PubMed ID: 19997873
[TBL] [Abstract][Full Text] [Related]
18. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
19. Baseline glutamate levels affect group I and II mGluRs in layer V pyramidal neurons of rat sensorimotor cortex.
Bandrowski AE; Huguenard JR; Prince DA
J Neurophysiol; 2003 Mar; 89(3):1308-16. PubMed ID: 12626613
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells.
Park JK; Lee SH; Kang JH; Nishio K; Saijo N; Kuh HJ
Anticancer Drugs; 2004 Sep; 15(8):809-18. PubMed ID: 15494644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
